Intellectual Property

Sepal Pharma understands that one of the key factors in the company's strength is the IP portfolio. The Company's granted and filed patents provide a strong and wide protection for all Jasmonate-based products developed for use in oncology and their use in various conditions.
At Sepal Pharma, we are dedicated to the ongoing development of our IP portfolio.

The review ONCOGENE highlights the work of Sepal's collaborators by dedicating an Editorial Commentary to the original mechanism of action jasmonates (Oncogene 27: 4633-4635, August 2008)